PTC Therapeutics, Inc. (PTCT)
PTCT moved a median of +0.01% 30 minutes after news, and +0.10% by the close. How PTCT actually reacts to news — the realized, point-in-time move the market made, measured across 686 labeled events over the last three years with zero look-ahead.
PTCT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.08% | 55% | 682 |
| 30-min | +0.01% | 50% | 684 |
| 60-min | +0.18% | 55% | 684 |
| to close | +0.10% | 55% | 681 |
| Middle 50% of PTCT reactions | -0.88% to +1.07% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 686 |
Half of all PTC Therapeutics, Inc. news events land between -0.88% and +1.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PTCT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 41 | +0.48% | 56% | +0.30% |
| Analyst downgrades | 22 | +0.83% | 59% | -0.07% |
| Coverage initiations | 23 | +0.05% | 52% | -0.21% |
| Rating reiterations | 122 | +0.08% | 55% | +0.14% |
| Price-target raises | 41 | -0.04% | 42% | -0.10% |
| Price-target cuts | 17 | -0.05% | 47% | +1.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how PTCT ranks against every other measured name →
That’s how PTCT usually reacts — get an email when it moves on news →Email me when PTCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PTCT's baseline. Nothing else.
Recent PTCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 | Press release | PR Newswire | +0.24% | — | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.82% | +5.77% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -0.42% | |
| PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy | Press release | PR Newswire | -0.36% | -0.42% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | -0.63% | |
| PTC Therapeutics to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.44% | -0.42% | |
| PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile | Press release | PR Newswire | +0.06% | +2.00% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | -1.60% | |
| PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program | Press release | PR Newswire | -1.17% | -1.60% | |
| Form 10-Q PTC THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.27% | -7.75% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -7.27% | -7.75% | |
| PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | -7.27% | -7.75% | |
| PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 | Press release | PR Newswire | -0.77% | -1.23% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +1.20% | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.91% | -0.75% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -0.33% | -2.83% | |
| PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes | Press release | PR Newswire | -0.33% | -2.83% | |
| PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes | Press release | PR Newswire | +0.82% | +6.52% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -0.38% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | -0.13% | |
| Form 10-Q PTC THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.59% | -0.51% | |
| Form 8-K PTC THERAPEUTICS, INC. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -4.59% | -0.51% | |
| PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -4.59% | -0.51% | |
| PTC Therapeutics to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +1.83% | +0.63% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -4.13% | -6.52% | |
| PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam | Press release | PR Newswire | -4.13% | -6.52% | |
| PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study | Press release | PR Newswire | +0.06% | +0.43% | |
| PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 | Press release | PR Newswire | -1.50% | -0.35% | |
| Form ARS PTC THERAPEUTICS, INC. For: Jan 31 | SEC filing · Form ARS | SEC EDGAR | -0.51% | -2.34% | |
| Form DEF 14A PTC THERAPEUTICS, INC. For: Jun 02 | SEC filing · Form DEF | SEC EDGAR | -0.51% | -2.34% | |
| Form DEFA14A PTC THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.51% | -2.34% | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.27% | +0.44% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.27% | +2.31% | |
| PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors | Press release | PR Newswire | +1.27% | +2.31% | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.36% | +2.98% | |
| PTC Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | +1.54% | -0.13% | |
| Form 10-K PTC THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.04% | +3.23% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +3.23% | |
| PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | PR Newswire | +1.04% | +3.23% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | -2.11% | |
| PTC Therapeutics Provides Regulatory Update on Translarna™ | Press release | PR Newswire | +0.32% | -2.11% | |
| PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 | Press release | PR Newswire | +0.31% | -1.94% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +2.25% | |
| PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference | Press release | PR Newswire | -2.96% | +0.39% | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.45% | -0.39% | |
| Form 8-K PTC THERAPEUTICS, INC. For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -1.42% | |
| PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan | Press release | PR Newswire | +1.83% | +0.97% | |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.83% | +0.97% | |
| PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -1.34% | -1.18% | |
| PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) | Press release | Canada Newswire | +0.12% | +0.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PTCT section they belong to.
Where else PTCT is measured.
PTCT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| Marinus Pharmaceuticals, Inc. (MRNS) | 687 | 0.00% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
| ONCOMED PHARMACEUTICALS (OMED) | 677 | -0.20% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PTC Therapeutics, Inc.'s median reaction calculated?
Every labeled PTCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 686 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of PTCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PTCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.